Delivery Order SPE2DB24D1205-SPE2DB25FDAHZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on September 9, 2025, with completion expected by September 30, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of supply fulfillment under the company's existing indefinite delivery contract vehicle. The product will be delivered to the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. The contract is firm fixed price with an ultimate completion date of August 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. The contract, which is not set-aside and was competitively awarded, has an ultimate completion date of August 8, 2025, with performance to be conducted at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency awarded a $9,374.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion scheduled for September 29, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDAHZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes valued at $2,343.59, with an ultimate completion date of October 1, 2025. This non-competitive delivery order utilizes firm fixed price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems. As the prime contractor on the DLA Troop Support Medical IDC, the company supplies a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare programs. Tezspire is a specialty biologic medication used in respiratory and immunological treatment, reflecting the company's role in delivering specialized pharmaceutical commodities essential to military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/10/25 |